Immunotherapy: New insights;Immuntherapie: Neue entwicklungen

Praxis

Volumn 91, Issue 51-52, 2002, Pages 2236-2246

  Geissler, M ^a   Weth, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Dendritic cells; Reverse immunology; Tumor antigens; Tumor vaccination

Indexed keywords

CANCER VACCINE; EPITOPE; SUBUNIT VACCINE; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANIMAL; B LYMPHOCYTE; CELL CULTURE; CLINICAL TRIAL; COMPARATIVE STUDY; DENDRITIC CELL; FORECASTING; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MOUSE; NEOPLASM; REVIEW; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CELLS, CULTURED; CLINICAL TRIALS; DENDRITIC CELLS; EPITOPES; FORECASTING; HUMANS; IMMUNE TOLERANCE; IMMUNITY, NATURAL; IMMUNIZATION; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINES, SUBUNIT;

EID: 0037132782     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.91.51.2236     Document Type: Review

References (47)

1. Swain S.L.: T cell subsets and the recognition of MHC class. Immunol Rev 74, 129-142, 1983.
2. Pardoll D.M., Topalian S.L.: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10, 588-594, 1998. (Pubitemid 28479193)
3. Raulet D.H.: Recognition events that inhibit and activate natural killer cells. Curr Opin Immunol 8, 372-377, 1996.
4. Kos F.J., Engleman E.G.: Immune regulation: a critical link between NK cells and CTLs. Immunol Today 17, 174-176, 1996. (Pubitemid 26114761)
5. Porcelli S.A., Modlin R.L.: The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 17, 297-329, 1999. (Pubitemid 29241127)
6. Kane L.P., Andres P.G., Howland K.C., et al.: Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol 2, 37-44, 2001. (Pubitemid 33704951)
7. Dong C., Juedes A.E., Temann U.A., et al.: ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409, 97-101, 2001. (Pubitemid 32098632)
8. McAdam A.J., Greenwald R.J., Levin M.A., et al.: ICOS is critical for CD40-mediated antibody class switching. Nature 409, 102-105, 2001. (Pubitemid 32098633)
9. Tafuri A., Shahinian A., Bladt F., et al.: ICOS is essential for effective T-helper-cell responses. Nature 409, 105-109, 2001. (Pubitemid 32098634)
10. Kurts C.: Cross-presentation: inducing CD8 T cell immunity and tolerance. J Mol Med 78, 326-332, 2000.
11. Motta I., Andre F., Lim A., et al.: Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 167, 1795-1802, 2001. (Pubitemid 32703184)
12. Wolfers J., Lozier A., Raposo G., et al.: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7, 297-303, 2001. (Pubitemid 32224344)
13. Zitvogel L., Angevin E., Tursz T.: Dendritic cell-based immunotherapy of cancer. Ann Oncol 11, 199-205, 2000.
14. Matzinger P.: Tolerance, danger, and the extended family. Annu Rev Immunol 12, 991-1045, 1994.
15. Mackay I.: Tolerance and Autoimmunity. N Engl J Med 344, 655-664, 2001.
16. Pardoll D.M.: Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96, 5340-5342, 1999.
17. Cohen I.R.: Discrimination and dialogue in the immune system. Semin Immunol 12, 215-219; discussion 257-344, 2000.
18. Anderson C.C., Matzinger P.: Danger: the view from the bottom of the cliff. Semin Immunol 12, 231-238, 2000. (Pubitemid 30479443)
19. Boon T., Cerottini J.C., Van den Eynde B., et al.: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12, 337-365, 1994. (Pubitemid 24140418)
20. Gilboa E.: The makings of a tumor rejection antigen. Immunity 11, 263-270, 1999.
21. Rosenberg S.A.: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287, 1999.
22. Sahin U., Tureci O., Pfreundschuh M.: Serological identification of human tumor antigens. Curr Opin Immunol 9, 709-716, 1997. (Pubitemid 27485301)
23. Schultze J.L., Maecker B. von Bergwelt-Baildon M.S., et al.: Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens. Vox Sang 80, 81-89, 2001. (Pubitemid 35345777)
24. Grimm C.F., Ortmann D., Mohr L., et al.: Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119, 1104-1112, 2000.
25. Van den Eynde B.J., van der Bruggen P.: T cell defined tumor antigens. Curr Opin Immunol 9, 684-693, 1997.
26. Vonderheide R.H., Hahn W.C., Schultze J.L., et al.: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673-679, 1999. (Pubitemid 29302920)
27. Schultze J.L., Vonderheide R.H.: From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 22, 516-523, 2001. (Pubitemid 32778580)
28. Bertoni R., Sidney J., Fowler P., et al.: Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 100, 503-513, 1997. (Pubitemid 27340496)
29. Chang K.M., Gruener N.H., Southwood S., et al.: Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 162, 1156-1164, 1999. (Pubitemid 29035448)
30. Altfeld M.A., Livingston B., Reshamwala N., et al.: Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol 75, 1301-1311, 2001. (Pubitemid 32094689)
31. Doolan D.L., Hoffman S.L., Southwood S., et al.: Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7, 97-112, 1997. (Pubitemid 27357268)
32. Geluk A., van Meijgaarden K.E., Franken K.L., et al.: Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J Immunol 165, 6463-6471, 2000.
33. Gross D.M., Forsthuber T., Tary-Lehmann M., et al.: Identification of LFA-1 as a candidate autoantigen in treatment- resistant Lyme arthritis. Science 281, 703-706, 1998. (Pubitemid 28390407)
34. Livingston B.D., Crimi C., Grey H., et al.: The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 159, 1383-1392, 1997. (Pubitemid 127484117)
35. Geissler M., Mohr L., Weth R., et al.: Immunotherapy Directed Against alpha-Fetoprotein Results in Autoimmune Liver Disease During Liver Regeneration in Mice. Gastroenterology 121, 931-939, 2001. (Pubitemid 32959402)
36. Ludewig B., Ochsenbein A.F., Odermatt B., et al.: Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 191, 795-803, 2000.
37. Kim N.W., Piatyszek M.A., Prowse K.R., et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015, 1994.
38. Hahn W.C., Counter C.M., Lundberg A.S., et al.: Creation of human tumour cells with defined genetic elements. Nature 400, 464-468, 1999. (Pubitemid 29361801)
39. Greenberg R.A., Chin L., Femino A., et al.: Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97, 515-525, 1999. (Pubitemid 29231174)
40. Heiser A., Maurice M.A., Yancey D.R., et al.: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 61, 3388-3393, 2001. (Pubitemid 32695030)
41. Glennie M.J., Johnson P.W.: Clinical trials of antibody therapy. Immunol Today 21, 403-410, 2000. (Pubitemid 30612302)
42. Altman J.D., Moss P.A., Goulder P.J., et al.: Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96, 1996. (Pubitemid 26332731)
43. Van Tendeloo V.F., Van Broeckhoven C., Berneman, Z.N.: Gene-based cancer vaccines: an ex vivo approach. Leukemia 15, 545-558, 2001. (Pubitemid 32273135)
44. Viret C., Lindemann A.: Tumor immunotherapy by vaccination with cytokine gene transfected cells. Int Rev Immunol 14, 193-212, 1997. (Pubitemid 27188578)
45. Fong L., Engleman E.G.: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18, 245-273, 2000. (Pubitemid 30365381)
46. Lee P.P., Yee C., Savage P.A., et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5, 677-685, 1999. (Pubitemid 29289432)
47. Geissler M. et al., Gentherapie des HCC, in Allgaier H.-P.: Das hepatozelluläre Karzinom. Reihe Science, UNIMED-Verlag, Bremen, 2001